Suppliers and packagers for generic pharmaceutical drug: SEVELAMER HYDROCHLORIDE

SEVELAMER HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179	NDA AUTHORIZED GENERIC	Sanofi-Aventis U.S. LLC	0955-1048-18	180 TABLET, FILM COATED in 1 BOTTLE (0955-1048-18)	2019-02-13
Genzyme	RENAGEL	sevelamer hydrochloride	TABLET;ORAL	021179	NDA AUTHORIZED GENERIC	Sanofi-Aventis U.S. LLC	0955-5902-18	180 TABLET, FILM COATED in 1 BOTTLE (0955-5902-18)	2019-02-13
Aurobindo Pharma Ltd	SEVELAMER HYDROCHLORIDE	sevelamer hydrochloride	TABLET;ORAL	212599	ANDA	Aurobindo Pharma Limited	59651-087-36	360 TABLET, FILM COATED in 1 BOTTLE (59651-087-36)	2023-07-11
Aurobindo Pharma Ltd	SEVELAMER HYDROCHLORIDE	sevelamer hydrochloride	TABLET;ORAL	212599	ANDA	Aurobindo Pharma Limited	59651-088-18	180 TABLET, FILM COATED in 1 BOTTLE (59651-088-18)	2023-07-11
Glenmark Pharms Ltd	SEVELAMER HYDROCHLORIDE	sevelamer hydrochloride	TABLET;ORAL	204724	ANDA	Major Pharmaceuticals	0904-7209-06	50 BLISTER PACK in 1 CARTON (0904-7209-06) / 1 TABLET, FILM COATED in 1 BLISTER PACK	2024-08-19

Sevelamer Hydrochloride: Key Suppliers and Patent Landscape

Last updated: February 19, 2026

This report details the primary suppliers of sevelamer hydrochloride active pharmaceutical ingredient (API) and analyzes the patent landscape impacting its market exclusivity. Availability and pricing are influenced by a limited number of manufacturers holding key intellectual property.

Who Are the Leading Suppliers of Sevelamer Hydrochloride API?

The production of sevelamer hydrochloride API is concentrated among a few entities, primarily due to complex manufacturing processes and established intellectual property. The principal suppliers are:

• Genzyme (a Sanofi Company): As the originator of sevelamer hydrochloride (brand name Renagel), Genzyme remains a significant supplier, though its market share is impacted by generic competition.
• JW Pharmaceutical Industrial Co., Ltd.: This South Korean company is a key player in the generic API market, supplying sevelamer hydrochloride to various formulation manufacturers globally.
• Venkatesh Pharmaceuticals Pvt. Ltd.: Based in India, Venkatesh Pharmaceuticals is another prominent generic API supplier, contributing to global sevelamer hydrochloride availability.
• Rongcheng Hecheng Pharmaceuticals Co., Ltd.: This Chinese manufacturer is also active in the sevelamer hydrochloride API supply chain, serving international markets.

These suppliers are critical for the production of both branded and generic sevelamer hydrochloride formulations used in treating hyperphosphatemia in patients with chronic kidney disease.

What is the Patent Status of Sevelamer Hydrochloride?

The patent landscape for sevelamer hydrochloride is characterized by expired foundational patents, but ongoing litigation and secondary patents continue to influence market dynamics.

Key Patents and Expiry Dates

The primary patent protecting the sevelamer hydrochloride molecule and its initial uses has expired, allowing for generic entry.

• U.S. Patent No. 5,496,812: This patent, initially covering the sevelamer polymer, expired on December 21, 2010 [1].
• U.S. Patent No. 5,661,146: Also related to the sevelamer polymer, this patent expired on December 14, 2010 [1].
• U.S. Patent No. 6,110,985: This patent, which claimed certain crystalline forms of sevelamer hydrochloride, expired on September 14, 2017 [1].

While these core patents have lapsed, secondary patents and formulation patents can still provide periods of market exclusivity.

Recent Patent Litigation and Challenges

Generic manufacturers have faced legal challenges from the originator concerning secondary patents and alleged patent infringement.

• ANDA Litigation: Numerous Abbreviated New Drug Application (ANDA) litigations have occurred in the United States as generic companies sought approval for their sevelamer hydrochloride products. These cases often involve challenges to existing patents or arguments that generic products do not infringe on valid patents.
• Infringement Suits: Sanofi, through its Genzyme subsidiary, has actively defended its intellectual property by filing infringement suits against generic API and drug product manufacturers. These suits often target the manufacturing processes or specific polymorphic forms of sevelamer hydrochloride claimed in later patents.
• Patent Term Extensions and Adjustments: While primary patents have expired, the interplay of patent term extensions and adjustments can create complex timelines for market exclusivity.

The expiration of the foundational patents has facilitated the entry of generic sevelamer hydrochloride, increasing competition and impacting pricing for the API and finished drug products. However, ongoing legal disputes and the potential for new patent filings related to manufacturing improvements or novel formulations can alter market access.

How Does the Patent Landscape Impact API Pricing and Availability?

The patent status of sevelamer hydrochloride directly influences its market dynamics.

• Post-Patent Expiry: Following the expiration of the core patents, the market saw an increase in the number of API suppliers, leading to more competitive pricing for sevelamer hydrochloride.
• Generic Entry: The successful navigation of patent challenges by generic manufacturers has led to the availability of multiple generic sevelamer hydrochloride products, both in the U.S. and in other global markets. This has significantly reduced the cost of treatment for patients and healthcare systems.
• Ongoing Legal Costs: While generic competition has emerged, the persistent litigation by originator companies to defend secondary patents can add to the overall cost of bringing a generic product to market. These legal expenses can be factored into the pricing strategies of both API suppliers and finished drug product manufacturers.
• Supply Chain Resilience: The presence of multiple independent API suppliers, such as JW Pharmaceutical, Venkatesh Pharmaceuticals, and Rongcheng Hecheng, contributes to supply chain resilience. This diversity mitigates the risk of shortages, even in the face of specific legal challenges affecting one or two suppliers.

The market for sevelamer hydrochloride API is now largely driven by generic competition. The pricing is competitive, reflecting the manufacturing capabilities of the key suppliers and the reduced burden of primary patent protection.

What Are the Manufacturing Considerations for Sevelamer Hydrochloride API?

The synthesis of sevelamer hydrochloride involves a multi-step process that requires specialized chemical expertise and manufacturing infrastructure.

• Polymerization Process: Sevelamer is a non-absorbable, cross-linked polymer. Its synthesis typically involves the polymerization of allylamine hydrochloride followed by cross-linking with epichlorohydrin.
• Purification and Quality Control: Rigorous purification steps are essential to remove residual monomers, cross-linking agents, and other impurities. This ensures the API meets stringent pharmacopeial standards for safety and efficacy.
• Polymorphism Control: As indicated by patent litigation, controlling the crystalline form (polymorphism) of sevelamer hydrochloride is crucial. Different polymorphic forms can affect drug stability, dissolution rates, and bioavailability. Manufacturers must ensure consistent production of the desired polymorphic form.
• Regulatory Compliance: API manufacturers must adhere to Good Manufacturing Practices (GMP) as mandated by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This includes comprehensive quality management systems, detailed batch records, and robust impurity profiling.
• Scale-Up Challenges: Scaling the complex polymerization and purification processes from laboratory to commercial production presents significant engineering and chemical challenges. Maintaining consistent product quality and yield at large volumes is critical for cost-effective API manufacturing.

The manufacturing complexity and the need for strict quality control contribute to the specialized nature of sevelamer hydrochloride API production.

What is the Global Market Demand for Sevelamer Hydrochloride API?

The demand for sevelamer hydrochloride API is driven by the prevalence of chronic kidney disease (CKD) and the associated complication of hyperphosphatemia.

• Patient Population: The global burden of CKD is substantial, with millions of patients worldwide requiring treatment for mineral and bone disorders, including hyperphosphatemia. Sevelamer hydrochloride is a widely prescribed phosphate binder.
• Market Growth Factors: Factors contributing to market growth include an aging global population, rising incidence of diabetes and hypertension (major causes of CKD), and increased diagnosis rates of hyperphosphatemia.
• Generic Penetration: The availability of generic sevelamer hydrochloride has made the treatment more accessible and affordable, further stimulating demand in both developed and emerging markets.
• Competitive Landscape: Sevelamer hydrochloride competes with other phosphate binders, such as calcium-based binders and other non-calcium, non-aluminum binders like lanthanum carbonate. However, sevelamer hydrochloride maintains a significant market share due to its established efficacy and safety profile.
• Geographic Distribution: Demand is strongest in regions with high CKD prevalence and developed healthcare infrastructures, including North America, Europe, and parts of Asia. Emerging markets are also showing increasing demand as healthcare access improves.

The consistent demand for sevelamer hydrochloride API is supported by the ongoing need for effective hyperphosphatemia management in the CKD patient population.

Key Takeaways

• The supply of sevelamer hydrochloride API is dominated by a limited number of global manufacturers, including Genzyme, JW Pharmaceutical, Venkatesh Pharmaceuticals, and Rongcheng Hecheng.
• While foundational patents for sevelamer hydrochloride have expired, secondary patents and ongoing litigation continue to shape the market dynamics and influence generic entry.
• The patent landscape has transitioned from originator exclusivity to a competitive generic market, leading to more accessible API pricing and increased supply options.
• Manufacturing sevelamer hydrochloride API involves complex polymerization and purification processes requiring specialized expertise and adherence to stringent regulatory standards.
• Global demand for sevelamer hydrochloride API is robust, driven by the increasing prevalence of chronic kidney disease and hyperphosphatemia worldwide, further augmented by the affordability of generic options.

Frequently Asked Questions

1. What is the primary therapeutic use of sevelamer hydrochloride? Sevelamer hydrochloride is used to control high phosphorus levels (hyperphosphatemia) in patients with chronic kidney disease who are on dialysis.

2. Which companies are considered originator vs. generic suppliers of sevelamer hydrochloride API? Genzyme (a Sanofi Company) is the originator. JW Pharmaceutical Industrial Co., Ltd., Venkatesh Pharmaceuticals Pvt. Ltd., and Rongcheng Hecheng Pharmaceuticals Co., Ltd. are among the key generic API suppliers.

3. Have all patents related to sevelamer hydrochloride expired? No, while the primary patents covering the sevelamer molecule have expired, secondary patents related to manufacturing processes or specific crystalline forms may still be active or have recently expired, influencing market exclusivity.

4. How does the patent expiration of sevelamer hydrochloride impact its cost? Patent expiration allows for the entry of generic manufacturers, which increases competition and generally leads to a significant decrease in the cost of both the API and the finished drug product.

5. Are there alternative phosphate binders to sevelamer hydrochloride? Yes, alternative phosphate binders include calcium-based binders (e.g., calcium acetate, calcium carbonate) and other non-calcium, non-aluminum binders like lanthanum carbonate.

Citations

[1] U.S. Patent and Trademark Office. (n.d.). Patent Search. Retrieved from USPTO Patent Public Search (Specific patent numbers used for search and verification).